DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB

Published:2024-08 Issue: Volume:46 Page:102016
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Wang Xuliren,Chi Weiru,Ma Yuwei^ORCID,Zhang Qi,Xue Jingyan,Shao Zhi-Ming,Xiu Bingqiu^ORCID,Wu Jiong,Chi Yayun^ORCID

Funder

National Natural Science Foundation of China

Shanghai Municipal Natural Science Foundation

Publisher

Elsevier BV

Reference25 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

4. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial;Cameron;Lancet,2017

5. Camps M., Nichols A., Arkinstall S.: Dual specificity phosphatases: a gene family for control of MAP kinase function. 2000, 14(1):6–16.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP